The role of the low molecular weight heparin in thrombotic and bleeding complication occurrence in patients with critical limb ischaemia, qualified to revascularization by the means of an artificial prosthesis

Abstract

Double antiplatelet therapy and low molecular weight heparin (LMWH) treatment increases the risk ofadverse bleeding events. The performed aggregometric analysis did not reveal any influence of LMWHon platelet aggregation and had a statistically insignificant influence on the clot properties analyzed bythe means of the thromboelastometry in patients with critical limb ischaemia.